Researchers find new potential drug...
The goal of harnessing the power of one's immune system to target and kill cancer cells just got a boost. New research from MD Anderson has yielded promising insights into a protein known as PDL1, which was found to be expressed in 20% of triple negative breast tumors.
Triple-negative disease is more aggressive than other types of breast cancer and is not fueled by female hormones estrogen and progesterone or by the cancer...
A step beyond chemo: MD Anderson's key roles in CLL drug approved...
The U.S. Food and Drug Administration today approved ibrutinib as a single treatment for chronic lymphocytic leukemia patients with...
Protein duo thwarts chromosomal scrambling and DNA breakage
Over the past few decades it has become increasingly clear that epigenetic changes - heritable changes in the cell that do not result...
Expressive writing reduces cancer-related...
In the largest expressive writing trial conducted on an oncology population, researchers from MD Anderson found those patients who recorded their deepest thoughts and emotions saw improved physical functioning and quality of life.
A cancer diagnosis may be experienced as a traumatic event causing depressive symptoms, sleep disturbance, fatigue and intrusive thoughts for patients. Managing the response to these thoughts and symptoms...